Identification

Name
Bromocriptine
Accession Number
DB01200  (APRD00622)
Type
Small Molecule
Groups
Approved, Investigational
Description

Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It is indicated for the management of signs and symptoms of Parkinsonian Syndrome. Bromocriptine also inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. It also causes sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly. Bromocriptine has been associated with pulmonary fibrosis.

Structure
Thumb
Synonyms
  • (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman
  • (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione
  • (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman
  • 2-Bromo-alpha-ergocryptine
  • 2-Bromo-alpha-ergokryptin
  • 2-Bromo-alpha-ergokryptine
  • 2-bromo-α-ergocryptine
  • 2-bromo-α-ergokryptin
  • 2-bromo-α-ergokryptine
  • Bromocriptina
  • Bromocriptinum
  • Bromocryptine
  • Bromoergocriptine
  • Bromoergocryptine
External IDs
SANDOZ 15-754
Product Ingredients
IngredientUNIICASInChI Key
Bromocriptine mesylateFFP983J3OD22260-51-1NOJMTMIRQRDZMT-GSPXQYRGSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BromocriptineTablet2.5 mgOralPharmel Inc1998-09-03Not applicableCanada
BromocriptineTablet2.5 mgOralAa Pharma Inc1994-12-31Not applicableCanada
BromocriptineCapsule5 mgOralPharmel Inc1998-09-03Not applicableCanada
BromocriptineCapsule5 mgOralAa Pharma Inc1997-01-08Not applicableCanada
Bromocriptine MesylateTablet2.5 mg/1OralSun Pharmaceutical Industries Limited2016-12-22Not applicableUs
Bromocriptine MesylateCapsule5 mg/1OralSun Pharmaceutical Industries Limited2016-12-22Not applicableUs
Bromocriptine-2.5 - Tab 2.5mgTablet2.5 mgOralPro Doc Limitee1996-12-312010-07-13Canada
Bromocriptine-5Capsule5 mgOralPro Doc Limitee1998-08-112010-07-13Canada
Co Bromocriptine Capsules 5mgCapsule5 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
Co Bromocriptine Tablets 2.5mgTablet2.5 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bromocriptine MesylateTablet2.5 mg/1OralPhysicians Total Care, Inc.2006-09-08Not applicableUs
Bromocriptine mesylateCapsule5 mg/1OralZydus Pharmaceuticals Usa, Inc.2009-01-23Not applicableUs
Bromocriptine MesylateTablet2.5 mg/1OralKaiser Foundations Hospitals2014-10-10Not applicableUs
Bromocriptine mesylateTablet2.5 mg/1OralKaiser Foundations Hospitals2017-02-14Not applicableUs
Bromocriptine MesylateCapsule5 mg/1OralAvera Mc Kennan Hospital2016-03-08Not applicableUs
Bromocriptine MesylateCapsule5 mg/1OralMylan Pharmaceuticals2013-06-17Not applicableUs
Bromocriptine MesylateCapsule5 mg/1OralAmerincan Health Packaging2010-01-132015-12-29Us
Bromocriptine mesylateTablet2.5 mg/1OralCarilion Materials Management2008-10-01Not applicableUs
Bromocriptine mesylateTablet2.5 mg/1OralSandoz1998-01-13Not applicableUs
Bromocriptine mesylateCapsule5 mg/1OralCadila Pharnmaceuticals2009-01-23Not applicableUs
International/Other Brands
Apo-Bromocriptine (Apotex) / Bagren (Serono (Brazil)) / Ergoset / Parlodel Snaptabs (Novartis) / Pravidel (Meda (Germany, Sweden), Novartis (Canada, discontinued))
Categories
UNII
3A64E3G5ZO
CAS number
25614-03-3
Weight
Average: 654.595
Monoisotopic: 653.221282062
Chemical Formula
C32H40BrN5O5
InChI Key
OZVBMTJYIDMWIL-AYFBDAFISA-N
InChI
InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1
IUPAC Name
(4R,7R)-10-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide
SMILES
[H][[email protected]@]12CCCN1C(=O)[[email protected]](CC(C)C)N1C(=O)[[email protected]](NC(=O)[[email protected]]3CN(C)[[email protected]]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[[email protected]@]21O)C(C)C

Pharmacology

Indication

For the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodopa in advanced cases with motor complications. Bromocriptine has also been used off-label to treat restless legs syndrome and neuroleptic malignant syndrome.

Structured Indications
Pharmacodynamics

Bromocriptine stimulates centrally-located dopaminergic receptors resulting in a number of pharmacologic effects. Five dopamine receptor types from two dopaminergic subfamilies have been identified. The dopaminergic D1 receptor subfamily consists of D1 and D5 subreceptors, which are associated with dyskinesias. The dopaminergic D2 receptor subfamily consists of D2, D3 and D4 subreceptors, which are associated with improvement of symptoms of movement disorders. Thus, agonist activity specific for D2 subfamily receptors, primarily D2 and D3 receptor subtypes, are the primary targets of dopaminergic antiparkinsonian agents. It is thought that postsynaptic D2 stimulation is primarily responsible for the antiparkinsonian effect of dopamine agonists, while presynaptic D2 stimulation confers neuroprotective effects. This semisynthetic ergot derivative exhibits potent agonist activity on dopamine D2-receptors. It also exhibits agonist activity (in order of decreasing binding affinity) on 5-hydroxytryptamine (5-HT)1D, dopamine D3, 5-HT1A, 5-HT2A, 5-HT1B, and 5-HT2C receptors, antagonist activity on α2A-adrenergic, α2C, α2B, and dopamine D1 receptors, partial agonist activity at receptor 5-HT2B, and inactivates dopamine D4 and 5-HT7 receptors. Parkinsonian Syndrome manifests when approximately 80% of dopaminergic activity in the nigrostriatal pathway of the brain is lost. As this striatum is involved in modulating the intensity of coordinated muscle activity (e.g. movement, balance, walking), loss of activity may result in dystonia (acute muscle contraction), Parkinsonism (including symptoms of bradykinesia, tremor, rigidity, and flattened affect), akathesia (inner restlessness), tardive dyskinesia (involuntary muscle movements usually associated with long-term loss of dopaminergic activity), and neuroleptic malignant syndrome, which manifests when complete blockage of nigrostriatal dopamine occurs. High dopaminergic activity in the mesolimbic pathway of the brain causes hallucinations and delusions; these side effects of dopamine agonists are manifestations seen in patients with schizophrenia who have overractivity in this area of the brain. The hallucinogenic side effects of dopamine agonists may also be due to 5-HT2A agonism. The tuberoinfundibular pathway of the brain originates in the hypothalamus and terminates in the pituitary gland. In this pathway, dopamine inhibits lactotrophs in anterior pituitary from secreting prolactin. Increased dopaminergic activity in the tuberoinfundibular pathway inhibits prolactin secretion making bromocriptine an effective agent for treating disorders associated with hypersecretion of prolactin. Pulmonary fibrosis may be associated bromocriptine’s agonist activity at 5-HT1B and 5-HT2B receptors.

Mechanism of action

The dopamine D2 receptor is a 7-transmembrane G-protein coupled receptor associated with Gi proteins. In lactotrophs, stimulation of dopamine D2 receptor causes inhibition of adenylyl cyclase, which decreases intracellular cAMP concentrations and blocks IP3-dependent release of Ca2+ from intracellular stores. Decreases in intracellular calcium levels may also be brought about via inhibition of calcium influx through voltage-gated calcium channels, rather than via inhibition of adenylyl cyclase. Additionally, receptor activation blocks phosphorylation of p42/p44 MAPK and decreases MAPK/ERK kinase phosphorylation. Inhibition of MAPK appears to be mediated by c-Raf and B-Raf-dependent inhibition of MAPK/ERK kinase. Dopamine-stimulated growth hormone release from the pituitary gland is mediated by a decrease in intracellular calcium influx through voltage-gated calcium channels rather than via adenylyl cyclase inhibition. Stimulation of dopamine D2 receptors in the nigrostriatal pathway leads to improvements in coordinated muscle activity in those with movement disorders.

TargetActionsOrganism
AD(2) dopamine receptor
agonist
Human
AD(3) dopamine receptor
agonist
Human
U5-hydroxytryptamine receptor 1D
agonist
Human
UAlpha-2A adrenergic receptor
agonist
Human
U5-hydroxytryptamine receptor 1A
agonist
Human
UAlpha-2C adrenergic receptor
agonist
Human
UAlpha-2B adrenergic receptor
agonist
Human
U5-hydroxytryptamine receptor 2B
agonist
Human
UD(4) dopamine receptor
antagonist
Human
U5-hydroxytryptamine receptor 2A
agonist
Human
U5-hydroxytryptamine receptor 1B
agonist
Human
U5-hydroxytryptamine receptor 2C
agonist
Human
UD(1B) dopamine receptor
agonist
Human
UD(1A) dopamine receptor
agonist
Human
UAlpha-1A adrenergic receptor
agonist
Human
UAlpha-1B adrenergic receptor
agonist
Human
UAlpha-1D adrenergic receptor
agonist
Human
U5-hydroxytryptamine receptor 7
antagonist
Human
Absorption

Approximately 28% of the oral dose is absorbed; however due to a substantial first pass effect, only 6% of the oral dose reaches the systemic circulation unchanged. Bromocriptine and its metabolites appear in the blood as early as 10 minutes following oral administration and peak plasma concentration are reached within 1-1.5 hours. Serum prolactin may be decreased within 2 hours or oral administration with a maximal effect achieved after 8 hours. Growth hormone concentrations in patients with acromegaly is reduced within 1-2 hours with a single oral dose of 2.5 mg and decreased growth hormone concentrations persist for at least 4-5 hours.

Volume of distribution
Not Available
Protein binding

90-96% bound to serum albumin

Metabolism

Completely metabolized by the liver, primarily by hydrolysis of the amide bond to produce lysergic acid and a peptide fragment, both inactive and non-toxic. Bromocriptine is metabolized by cytochrome P450 3A4 and excreted primarily in the feces via biliary secretion.

Route of elimination

Parent drug and metabolites are almost completely excreted via the liver, and only 6% eliminated via the kidney.

Half life

2-8 hours

Clearance
Not Available
Toxicity

Symptoms of overdosage include nausea, vomiting, and severe hypotension. The most common adverse effects include nausea, headache, vertigo, constipation, light-headedness, abdominal cramps, nasal congestion, diarrhea, and hypotension.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Bromocriptine can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Bromocriptine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Bromocriptine can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe metabolism of Bromocriptine can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcebutololBromocriptine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Aceprometazine.Approved
AcetaminophenThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Acetophenazine.Approved
Acetyl sulfisoxazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Acetyl sulfisoxazole.Approved, Vet Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Bromocriptine.Approved, Vet Approved
AdrafinilBromocriptine may increase the hypertensive and vasoconstricting activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Bromocriptine.Approved
AlaproclateAlaproclate may increase the hypoglycemic activities of Bromocriptine.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Aldesleukin.Approved
AliskirenThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Aliskiren.Approved, Investigational
AlmotriptanBromocriptine may increase the vasoconstricting activities of Almotriptan.Approved, Investigational
AlogliptinThe serum concentration of Bromocriptine can be increased when it is combined with Alogliptin.Approved
AloxiprinAloxiprin may increase the hypoglycemic activities of Bromocriptine.Experimental
Alpha-1-proteinase inhibitorThe serum concentration of Bromocriptine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprazolamThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Alprazolam.Approved, Illicit, Investigational
AlprenololBromocriptine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmbroxolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ambroxol.Approved, Investigational
AmibegronBromocriptine may increase the hypertensive and vasoconstricting activities of Amibegron.Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Bromocriptine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Amiloride.Approved
AmineptineAmineptine may decrease the antihypertensive activities of Bromocriptine.Illicit, Withdrawn
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Bromocriptine.Approved
AmiodaroneThe metabolism of Bromocriptine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Bromocriptine.Approved, Investigational
AmitrazBromocriptine may increase the hypertensive and vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Bromocriptine.Approved
AmitriptylinoxideAmitriptylinoxide may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Bromocriptine.Approved, Illicit
AmoxapineAmoxapine may decrease the antihypertensive activities of Bromocriptine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Amperozide.Experimental
AmphetamineThe metabolism of Bromocriptine can be decreased when combined with Amphetamine.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bromocriptine.Approved, Investigational
AmprenavirThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Amprenavir.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Amyl Nitrite.Approved
AnastrozoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Anastrozole.Approved, Investigational
AnisodamineBromocriptine may increase the hypertensive and vasoconstricting activities of Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Antipyrine.Approved, Investigational
Antithrombin III humanThe serum concentration of Bromocriptine can be increased when it is combined with Antithrombin III human.Approved
ApalutamideThe serum concentration of Bromocriptine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Bromocriptine can be increased when it is combined with Apixaban.Approved
ApomorphineBromocriptine may increase the vasoconstricting activities of Apomorphine.Approved, Investigational
ApraclonidineBromocriptine may increase the hypertensive and vasoconstricting activities of Apraclonidine.Approved
AprepitantThe serum concentration of Bromocriptine can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Bromocriptine can be increased when it is combined with Aprotinin.Approved, Investigational, Withdrawn
ArbutamineBromocriptine may increase the hypertensive and vasoconstricting activities of Arbutamine.Approved
ArformoterolBromocriptine may increase the hypertensive and vasoconstricting activities of Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Bromocriptine can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Bromocriptine.Approved, Investigational
ArotinololBromocriptine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Arsenic trioxide.Approved, Investigational
AsenapineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Asenapine.Approved
AstemizoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Bromocriptine.Approved, Investigational, Withdrawn
AtazanavirThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Atazanavir.Approved, Investigational
AtenololBromocriptine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AtomoxetineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Azaperone.Investigational, Vet Approved
AzelastineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Azilsartan medoxomil.Approved, Investigational
AzithromycinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Azithromycin.Approved
BalsalazideBalsalazide may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Bromocriptine.Experimental
BarbitalBarbital may increase the hypotensive activities of Bromocriptine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Bromocriptine.Approved
BatimastatThe serum concentration of Bromocriptine can be increased when it is combined with Batimastat.Experimental
BefunololBromocriptine may increase the hypertensive and vasoconstricting activities of Befunolol.Experimental
BenazeprilThe serum concentration of Bromocriptine can be increased when it is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bendroflumethiazide.Approved
BenmoxinThe metabolism of Bromocriptine can be decreased when combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Benperidol.Approved, Investigational
BenzamidineThe serum concentration of Bromocriptine can be increased when it is combined with Benzamidine.Experimental
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Bromocriptine.Approved, Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Betamethasone.Approved, Vet Approved
BetaxololBromocriptine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved, Investigational
BevantololBromocriptine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BicalutamideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bicalutamide.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bifeprunox.Investigational
BifonazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bifonazole.Approved, Investigational
BisoprololBromocriptine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BitolterolBromocriptine may increase the hypertensive and vasoconstricting activities of Bitolterol.Withdrawn
BivalirudinThe serum concentration of Bromocriptine can be increased when it is combined with Bivalirudin.Approved, Investigational
BlonanserinThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Blonanserin.Approved, Investigational
BoceprevirThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Boceprevir.Approved, Withdrawn
BopindololBromocriptine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bromocriptine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Bromocriptine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Bromocriptine.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Brexpiprazole.Approved, Investigational
BrimonidineBromocriptine may increase the hypertensive and vasoconstricting activities of Brimonidine.Approved
BrofaromineThe metabolism of Bromocriptine can be decreased when combined with Brofaromine.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bromperidol.Approved, Investigational
BucindololBromocriptine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BufuralolBromocriptine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bupivacaine.Approved, Investigational
BupranololBromocriptine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Bromocriptine.Approved, Investigational
ButaperazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Butaperazine.Experimental
ButriptylineButriptyline may decrease the antihypertensive activities of Bromocriptine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Bromocriptine.Approved
CaffeineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Caffeine.Approved
CamostatThe serum concentration of Bromocriptine can be increased when it is combined with Camostat.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Candesartan cilexetil.Approved
CandoxatrilThe serum concentration of Bromocriptine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Bromocriptine can be increased when it is combined with Candoxatrilat.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Capsaicin.Approved
CaptoprilThe serum concentration of Bromocriptine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Bromocriptine can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the hypoglycemic activities of Bromocriptine.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Carbetocin.Approved, Investigational
CarbomycinThe serum concentration of Bromocriptine can be increased when it is combined with Carbomycin.Vet Approved
CariprazineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Cariprazine.Approved, Investigational
CaroxazoneThe metabolism of Bromocriptine can be decreased when combined with Caroxazone.Withdrawn
CarteololBromocriptine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolBromocriptine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Caspofungin.Approved
CeliprololBromocriptine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Bromocriptine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Bromocriptine.Approved, Withdrawn
ChloramphenicolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Chloramphenicol.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Chlorothiazide.Approved, Vet Approved
ChlorproethazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Chlorproethazine.Experimental
ChlorpromazineThe therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Bromocriptine.Approved, Investigational, Vet Approved
ChlorprothixeneThe therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Bromocriptine.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Chlorzoxazone.Approved
CholesterolThe serum concentration of Bromocriptine can be increased when it is combined with Cholesterol.Approved, Experimental, Investigational
ChymostatinThe serum concentration of Bromocriptine can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Bromocriptine can be increased when it is combined with Cilastatin.Approved, Investigational
CilazaprilThe serum concentration of Bromocriptine can be increased when it is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cilnidipine.Approved, Investigational
CilostazolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cilostazol.Approved, Investigational
Cimicifuga racemosaThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cimicifuga racemosa.Approved, Experimental
CinoxacinCinoxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ciprofloxacin.Approved, Investigational
CirazolineBromocriptine may increase the hypertensive activities of Cirazoline.Experimental
CisaprideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cisapride.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Bromocriptine.Approved
ClarithromycinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clemastine.Approved, Investigational
ClenbuterolBromocriptine may increase the hypertensive and vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clevidipine.Approved, Investigational
ClindamycinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clindamycin.Approved, Vet Approved
ClofarabineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clofarabine.Approved, Investigational
ClofazimineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clofazimine.Approved, Investigational
ClomifeneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clomifene.Approved, Investigational
ClomipramineClomipramine may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational, Vet Approved
ClonidineBromocriptine may increase the hypertensive and vasoconstricting activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clopenthixol.Experimental
CloranololBromocriptine may increase the atrioventricular blocking (AV block) activities of Cloranolol.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clozapine.Approved
CobicistatThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Bromocriptine.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Bromocriptine.Approved, Investigational
Cortisone acetateThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cortisone acetate.Approved, Investigational
CrizotinibThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cyamemazine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bromocriptine.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Bromocriptine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Bromocriptine.Approved
DabrafenibThe serum concentration of Bromocriptine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DalfopristinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dalfopristin.Approved
DanazolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Danazol.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dapiprazole.Approved
DapoxetineDapoxetine may increase the hypoglycemic activities of Bromocriptine.Investigational
DarexabanThe serum concentration of Bromocriptine can be increased when it is combined with Darexaban.Investigational
DarunavirThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Darunavir.Approved
DasatinibThe serum concentration of Bromocriptine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Bromocriptine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelanzomibThe serum concentration of Bromocriptine can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Bromocriptine can be increased when it is combined with Delapril.Experimental
DelavirdineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Delavirdine.Approved
DersalazineDersalazine may increase the hypoglycemic activities of Bromocriptine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Desipramine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Desvenlafaxine.Approved, Investigational
DetomidineBromocriptine may increase the hypertensive and vasoconstricting activities of Detomidine.Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineBromocriptine may increase the hypertensive and vasoconstricting activities of Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Bromocriptine.Approved
DextropropoxypheneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DiazepamThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Diazepam.Approved, Illicit, Investigational, Vet Approved
DibenzepinDibenzepin may decrease the antihypertensive activities of Bromocriptine.Experimental
DiclofenamideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Diclofenamide.Approved, Investigational
DiethylstilbestrolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Diethylstilbestrol.Approved, Investigational
DiflunisalDiflunisal may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Bromocriptine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Bromocriptine.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Bromocriptine.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Bromocriptine.Approved, Investigational
DiltiazemThe metabolism of Bromocriptine can be decreased when combined with Diltiazem.Approved, Investigational
DimetacrineDimetacrine may decrease the antihypertensive activities of Bromocriptine.Approved, Withdrawn
Dimethyl sulfoxideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dimethyl sulfoxide.Approved, Vet Approved
DinutuximabThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dinutuximab.Approved, Investigational
DipivefrinBromocriptine may increase the hypertensive and vasoconstricting activities of Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dipyridamole.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dixyrazine.Experimental
DobutamineBromocriptine may increase the hypertensive and vasoconstricting activities of Dobutamine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Docetaxel.Approved, Investigational
DolasetronDolasetron may increase the serotonergic activities of Bromocriptine.Approved, Investigational
DopexamineBromocriptine may increase the hypertensive and vasoconstricting activities of Dopexamine.Approved, Investigational
DosulepinDosulepin may decrease the antihypertensive activities of Bromocriptine.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Doxazosin.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Doxorubicin.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Bromocriptine.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dronedarone.Approved
DroperidolThe therapeutic efficacy of Droperidol can be decreased when used in combination with Bromocriptine.Approved, Vet Approved
DroxidopaBromocriptine may increase the hypertensive activities of Droxidopa.Approved, Investigational
DuloxetineBromocriptine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EcabetThe serum concentration of Bromocriptine can be increased when it is combined with Ecabet.Approved, Investigational
EconazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Econazole.Approved
EcopipamThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Bromocriptine.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Efonidipine.Approved, Investigational
ElafinThe serum concentration of Bromocriptine can be increased when it is combined with Elafin.Investigational
ElbasvirThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Elbasvir.Approved
EletriptanBromocriptine may increase the vasoconstricting activities of Eletriptan.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Empagliflozin.Approved
EnalaprilThe serum concentration of Bromocriptine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Bromocriptine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Bromocriptine can be increased when it is combined with Enalkiren.Experimental
EnasidenibThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Enasidenib.Approved, Investigational
EnoxacinEnoxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
EnzalutamideThe serum concentration of Bromocriptine can be decreased when it is combined with Enzalutamide.Approved
EpanololBromocriptine may increase the atrioventricular blocking (AV block) activities of Epanolol.Experimental
EphedrineBromocriptine may increase the hypertensive and vasoconstricting activities of Ephedrine.Approved
Epigallocatechin GallateThe serum concentration of Bromocriptine can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinastineBromocriptine may increase the hypertensive and vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineBromocriptine may increase the hypertensive and vasoconstricting activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Eprosartan.Approved
Ergoloid mesylateErgoloid mesylate may increase the vasoconstricting activities of Bromocriptine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Bromocriptine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Bromocriptine.Approved
ErythromycinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Bromocriptine.Approved, Investigational
EsmololBromocriptine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Etacrynic acid.Approved, Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Bromocriptine.Approved
EtilefrineBromocriptine may increase the hypertensive and vasoconstricting activities of Etilefrine.Withdrawn
EtoperidoneEtoperidone may increase the hypoglycemic activities of Bromocriptine.Withdrawn
EtoposideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Etoposide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Etoricoxib.Approved, Investigational
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Bromocriptine.Approved
EzetimibeThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ezetimibe.Approved
FaldaprevirThe serum concentration of Bromocriptine can be increased when it is combined with Faldaprevir.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fenoldopam.Approved
FenoterolBromocriptine may increase the hypertensive and vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FimasartanThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fimasartan.Approved, Investigational
FleroxacinFleroxacin may increase the hypoglycemic activities of Bromocriptine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Bromocriptine can be decreased when combined with Fluconazole.Approved, Investigational
FlumequineFlumequine may increase the hypoglycemic activities of Bromocriptine.Withdrawn
FluoxetineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluoxetine.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Bromocriptine.Approved, Illicit
FlupentixolThe therapeutic efficacy of Flupentixol can be decreased when used in combination with Bromocriptine.Approved, Investigational, Withdrawn
FluphenazineThe therapeutic efficacy of Fluphenazine can be decreased when used in combination with Bromocriptine.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Bromocriptine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluvoxamine.Approved, Investigational
FormoterolBromocriptine may increase the hypertensive and vasoconstricting activities of Formoterol.Approved, Investigational
FosamprenavirThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Bromocriptine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Bromocriptine can be increased when it is combined with Fosinopril.Approved
FosnetupitantThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fosnetupitant.Approved
FosphenytoinThe metabolism of Bromocriptine can be increased when combined with Fosphenytoin.Approved, Investigational
FrovatriptanBromocriptine may increase the vasoconstricting activities of Frovatriptan.Approved, Investigational
FurazolidoneThe metabolism of Bromocriptine can be decreased when combined with Furazolidone.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Bromocriptine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabexateThe serum concentration of Bromocriptine can be increased when it is combined with Gabexate.Investigational
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Bromocriptine.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
GeldanamycinThe serum concentration of Bromocriptine can be increased when it is combined with Geldanamycin.Experimental, Investigational
GemfibrozilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
GLPG-0492GLPG-0492 may increase the hypoglycemic activities of Bromocriptine.Investigational
GlyburideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Glyburide.Approved
Glycerol PhenylbutyrateThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Glycerol Phenylbutyrate.Approved
GM6001The serum concentration of Bromocriptine can be increased when it is combined with GM6001.Experimental
GranisetronGranisetron may increase the serotonergic activities of Bromocriptine.Approved, Investigational
GrepafloxacinGrepafloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational, Withdrawn
GuacetisalGuacetisal may increase the hypoglycemic activities of Bromocriptine.Experimental
GuanabenzBromocriptine may increase the hypertensive and vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineBromocriptine may increase the hypertensive and vasoconstricting activities of Guanfacine.Approved, Investigational
HaloperidolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Halothane.Approved, Vet Approved
HarmalineThe metabolism of Bromocriptine can be decreased when combined with Harmaline.Experimental
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the hypoglycemic activities of Bromocriptine.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Bromocriptine.Approved
HexoprenalineBromocriptine may increase the hypertensive and vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineBromocriptine may increase the hypertensive and vasoconstricting activities of Higenamine.Investigational
HistamineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Histamine.Approved, Investigational
HydracarbazineThe metabolism of Bromocriptine can be decreased when combined with Hydracarbazine.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Hydroflumethiazide.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Bromocriptine.Approved
IdelalisibThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Idelalisib.Approved
IdraparinuxThe serum concentration of Bromocriptine can be increased when it is combined with Idraparinux.Investigational
IfosfamideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ifosfamide.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Iloprost.Approved, Investigational
ImatinibThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Imatinib.Approved
ImidaprilThe serum concentration of Bromocriptine can be increased when it is combined with Imidapril.Investigational
ImipramineImipramine may decrease the antihypertensive activities of Bromocriptine.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Bromocriptine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Indapamide.Approved
IndenololBromocriptine may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndinavirThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Indinavir.Approved
IndisulamThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Indisulam.Investigational
IndoraminThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Indoramin.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Bromocriptine.Approved, Investigational
IprindoleIprindole may decrease the antihypertensive activities of Bromocriptine.Experimental
IproclozideThe metabolism of Bromocriptine can be decreased when combined with Iproclozide.Withdrawn
IproniazidThe metabolism of Bromocriptine can be decreased when combined with Iproniazid.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Irbesartan.Approved, Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Irinotecan.Approved, Investigational
IsavuconazoleThe serum concentration of Bromocriptine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe metabolism of Bromocriptine can be decreased when combined with Isocarboxazid.Approved
IsoetarineBromocriptine may increase the hypertensive and vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Isoflurane.Approved, Vet Approved
IsoflurophateThe serum concentration of Bromocriptine can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Isoniazid.Approved, Investigational
IsoprenalineBromocriptine may increase the hypertensive and vasoconstricting activities of Isoprenaline.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineBromocriptine may increase the hypertensive and vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Isradipine.Approved, Investigational
ItraconazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Bromocriptine can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Bromocriptine can be increased when it is combined with Ixazomib.Approved, Investigational
JosamycinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Josamycin.Approved, Investigational
KetazolamThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ketazolam.Approved
KetoconazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Bromocriptine can be increased when it is combined with Kitasamycin.Experimental
LabetalolBromocriptine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LacidipineBromocriptine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LandiololBromocriptine may increase the atrioventricular blocking (AV block) activities of Landiolol.Investigational
LanreotideThe serum concentration of Bromocriptine can be increased when it is combined with Lanreotide.Approved
LansoprazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lansoprazole.Approved, Investigational
LapatinibThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Bromocriptine.Approved
LepirudinThe serum concentration of Bromocriptine can be increased when it is combined with Lepirudin.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lercanidipine.Approved, Investigational
LetaxabanThe serum concentration of Bromocriptine can be increased when it is combined with Letaxaban.Investigational
LevobunololLevobunolol may increase the vasoconstricting activities of Bromocriptine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Levobupivacaine.Approved, Investigational
LevodopaBromocriptine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Levomilnacipran.Approved, Investigational
LevosalbutamolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Levosalbutamol.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Levosimendan.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Linagliptin.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Bromocriptine.Approved, Investigational
LisinoprilThe serum concentration of Bromocriptine can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideBromocriptine may increase the vasoconstricting activities of Lisuride.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lithium.Approved
LofepramineLofepramine may decrease the antihypertensive activities of Bromocriptine.Experimental
LofexidineBromocriptine may increase the hypertensive and vasoconstricting activities of Lofexidine.Approved, Investigational
LomitapideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lomitapide.Approved, Investigational
LomustineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lomustine.Approved, Investigational
LopinavirThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Loratadine.Approved, Investigational
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Bromocriptine.Approved
LorpiprazoleThe serum concentration of Bromocriptine can be increased when it is combined with Lorpiprazole.Approved
LosartanThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Losartan.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Bromocriptine.Approved, Investigational
LoxapineThe therapeutic efficacy of Loxapine can be decreased when used in combination with Bromocriptine.Approved
LuliconazoleThe serum concentration of Bromocriptine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Bromocriptine can be decreased when it is combined with Lumacaftor.Approved
LumateperoneThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Lumateperone.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lurasidone.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Bromocriptine.Illicit, Investigational, Withdrawn
ManidipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Bromocriptine.Approved, Investigational
MebanazineThe metabolism of Bromocriptine can be decreased when combined with Mebanazine.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Mecamylamine.Approved, Investigational
MedetomidineBromocriptine may increase the hypertensive and vasoconstricting activities of Medetomidine.Vet Approved
MefloquineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Mefloquine.Approved, Investigational
MelagatranThe serum concentration of Bromocriptine can be increased when it is combined with Melagatran.Experimental
MelitracenMelitracen may decrease the antihypertensive activities of Bromocriptine.Experimental, Investigational
MelperoneThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Melperone.Approved, Investigational
MephentermineBromocriptine may increase the hypertensive activities of Mephentermine.Approved
MepindololBromocriptine may increase the atrioventricular blocking (AV block) activities of Mepindolol.Experimental
MequitazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Mequitazine.Approved
MesalazineMesalazine may increase the hypoglycemic activities of Bromocriptine.Approved
MesoridazineThe therapeutic efficacy of Mesoridazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
MesteroloneMesterolone may increase the hypoglycemic activities of Bromocriptine.Experimental
MetaraminolBromocriptine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Bromocriptine.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Methazolamide.Approved
MethimazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Methimazole.Approved
MethohexitalMethohexital may increase the hypotensive activities of Bromocriptine.Approved
MethotrimeprazineThe therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
MethoxamineBromocriptine may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineBromocriptine may increase the hypertensive and vasoconstricting activities of Methoxyphenamine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Methyclothiazide.Approved
Methyl salicylateMethyl salicylate may increase the hypoglycemic activities of Bromocriptine.Approved, Vet Approved
MethyldopaBromocriptine may increase the hypertensive and vasoconstricting activities of Methyldopa.Approved
Methylene blueThe metabolism of Bromocriptine can be decreased when combined with Methylene blue.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Bromocriptine.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Bromocriptine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Bromocriptine.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Methylprednisolone.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Bromocriptine.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Bromocriptine.Approved
MetipranololMetipranolol may increase the vasoconstricting activities of Bromocriptine.Approved
MetoclopramideThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Metolazone.Approved
MetoprololBromocriptine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MetronidazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Metronidazole.Approved
MetyraponeThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Metyrapone.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Bromocriptine.Experimental
MianserinThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Mianserin.Approved, Investigational
MibefradilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Midazolam.Approved, Illicit
MidodrineBromocriptine may increase the hypertensive activities of Midodrine.Approved
MifepristoneThe serum concentration of Bromocriptine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Milnacipran.Approved, Investigational
MinaprineThe metabolism of Bromocriptine can be decreased when combined with Minaprine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Minoxidil.Approved, Investigational
MirabegronBromocriptine may increase the hypertensive and vasoconstricting activities of Mirabegron.Approved
MirtazapineMirtazapine may decrease the antihypertensive activities of Bromocriptine.Approved
MitotaneThe serum concentration of Bromocriptine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe metabolism of Bromocriptine can be decreased when combined with Moclobemide.Approved, Investigational
ModafinilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Bromocriptine can be increased when it is combined with Moexipril.Approved
MolindoneThe therapeutic efficacy of Molindone can be decreased when used in combination with Bromocriptine.Approved
MoperoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Moperone.Experimental
MorphineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Morphine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Mosapramine.Experimental
MoxonidineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Moxonidine.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Bromocriptine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nabilone.Approved, Investigational
NadololBromocriptine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NafamostatThe serum concentration of Bromocriptine can be increased when it is combined with Nafamostat.Approved, Investigational
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Bromocriptine.Approved
NaluzotanBromocriptine may increase the vasoconstricting activities of Naluzotan.Investigational
NandroloneNandrolone may increase the hypoglycemic activities of Bromocriptine.Experimental, Investigational
Nandrolone decanoateNandrolone decanoate may increase the hypoglycemic activities of Bromocriptine.Approved, Illicit
NaphazolineBromocriptine may increase the hypertensive and vasoconstricting activities of Naphazoline.Approved
NaratriptanBromocriptine may increase the vasoconstricting activities of Naratriptan.Approved, Investigational
NebivololBromocriptine may increase the hypertensive and vasoconstricting activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Bromocriptine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Bromocriptine.Investigational
NesiritideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Bromocriptine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nevirapine.Approved
NialamideThe metabolism of Bromocriptine can be decreased when combined with Nialamide.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nicardipine.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Bromocriptine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Bromocriptine.Approved, Investigational
NicotinamideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nicotinamide.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nifedipine.Approved
NilotinibThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nilvadipine.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nimodipine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Bromocriptine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nitric Oxide.Approved
NitroaspirinThe serum concentration of Bromocriptine can be increased when it is combined with Nitroaspirin.Investigational
NitroglycerinThe bioavailability of Bromocriptine can be increased when combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nitrous acid.Approved, Investigational
NorepinephrineBromocriptine may increase the hypertensive and vasoconstricting activities of Norepinephrine.Approved
NorfenefrineBromocriptine may increase the hypertensive and vasoconstricting activities of Norfenefrine.Experimental
NorfloxacinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Norfloxacin.Approved
NortriptylineNortriptyline may decrease the antihypertensive activities of Bromocriptine.Approved
NoscapineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Noscapine.Investigational
NylidrinBromocriptine may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Obinutuzumab.Approved, Investigational
OctamoxinThe metabolism of Bromocriptine can be decreased when combined with Octamoxin.Withdrawn
OctopamineBromocriptine may increase the hypertensive and vasoconstricting activities of Octopamine.Experimental
OctreotideThe serum concentration of Bromocriptine can be increased when it is combined with Octreotide.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Olanzapine.Approved, Investigational
OlaparibThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Olaparib.Approved
OleandomycinThe serum concentration of Bromocriptine can be increased when it is combined with Oleandomycin.Vet Approved
OlmesartanThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Olmesartan.Approved, Investigational
OlodaterolBromocriptine may increase the hypertensive and vasoconstricting activities of Olodaterol.Approved
OlsalazineOlsalazine may increase the hypoglycemic activities of Bromocriptine.Approved
OmapatrilatThe serum concentration of Bromocriptine can be increased when it is combined with Omapatrilat.Investigational
OmeprazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the serotonergic activities of Bromocriptine.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Bromocriptine.Investigational
OrciprenalineBromocriptine may increase the hypertensive and vasoconstricting activities of Orciprenaline.Approved
OsanetantThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Bromocriptine can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Bromocriptine can be increased when it is combined with Otamixaban.Investigational
OxandroloneOxandrolone may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
Oxolinic acidOxolinic acid may increase the hypoglycemic activities of Bromocriptine.Experimental
OxprenololBromocriptine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Oxybutynin.Approved, Investigational
OxyfedrineBromocriptine may increase the hypertensive and vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineBromocriptine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.Approved, Investigational
OxymetholoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Oxymetholone.Approved, Illicit
OxypertineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Oxypertine.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Bromocriptine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Bromocriptine.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Papaverine.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Paramethasone.Approved
PargylineThe metabolism of Bromocriptine can be decreased when combined with Pargyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Bromocriptine.Approved, Investigational
PasireotideThe serum concentration of Bromocriptine can be increased when it is combined with Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Bromocriptine.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Bromocriptine.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Bromocriptine.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Bromocriptine.Approved
PenbutololBromocriptine may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Penfluridol.Experimental
PentobarbitalThe metabolism of Bromocriptine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
Peppermint oilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Peppermint oil.Approved, Investigational
PerazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Perazine.Approved, Investigational
PergolideBromocriptine may increase the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Bromocriptine can be increased when it is combined with Perindopril.Approved
PerospironeThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Perospirone.Approved
PerphenazineThe therapeutic efficacy of Perphenazine can be decreased when used in combination with Bromocriptine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Bromocriptine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Phenelzine.Approved
PheniprazineThe metabolism of Bromocriptine can be decreased when combined with Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Bromocriptine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Phenoxybenzamine.Approved
PhenoxypropazineThe metabolism of Bromocriptine can be decreased when combined with Phenoxypropazine.Withdrawn
PhentolamineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Phentolamine.Approved
Phenyl aminosalicylatePhenyl aminosalicylate may increase the hypoglycemic activities of Bromocriptine.Approved
PhenylephrineBromocriptine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineBromocriptine may increase the hypertensive and vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Bromocriptine can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Bromocriptine can be increased when it is combined with Phosphoramidon.Experimental
PiclozotanBromocriptine may increase the vasoconstricting activities of Piclozotan.Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pilocarpine.Approved, Investigational
PimavanserinThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pimozide.Approved
PindololBromocriptine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pipamperone.Approved, Investigational
Pipemidic acidPipemidic acid may increase the hypoglycemic activities of Bromocriptine.Experimental
PiperaquineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Piperaquine.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pipotiazine.Approved, Investigational
PirbuterolBromocriptine may increase the hypertensive and vasoconstricting activities of Pirbuterol.Approved
PirlindoleThe metabolism of Bromocriptine can be decreased when combined with Pirlindole.Approved
Piromidic acidPiromidic acid may increase the hypoglycemic activities of Bromocriptine.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Bromocriptine.Approved
PitolisantThe serum concentration of Bromocriptine can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazineThe metabolism of Bromocriptine can be decreased when combined with Pivhydrazine.Withdrawn
Platelet Activating FactorBromocriptine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Experimental
PosaconazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololBromocriptine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Bromocriptine.Approved
PrazosinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Prazosin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Prednisone.Approved, Vet Approved
PrenalterolBromocriptine may increase the hypertensive and vasoconstricting activities of Prenalterol.Experimental
PrimaquineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Primaquine.Approved
PrimidoneThe metabolism of Bromocriptine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Bromocriptine can be increased when it is combined with Prinomastat.Investigational
ProcarbazineThe metabolism of Bromocriptine can be decreased when combined with Procarbazine.Approved, Investigational
ProcaterolBromocriptine may increase the hypertensive and vasoconstricting activities of Procaterol.Approved, Investigational
ProchlorperazineThe therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Bromocriptine.Approved, Vet Approved
ProgesteroneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Progesterone.Approved, Vet Approved
PromazineThe therapeutic efficacy of Promazine can be decreased when used in combination with Bromocriptine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Bromocriptine.Approved, Investigational
PropericiazineThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololBromocriptine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Prothipendyl.Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Bromocriptine.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Bromocriptine.Approved
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Bromocriptine.Investigational
PseudoephedrineBromocriptine may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.Approved
QuetiapineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Quetiapine.Approved
QuinaprilThe serum concentration of Bromocriptine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Quinine.Approved
QuinupristinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Quinupristin.Approved
RabeprazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Rabeprazole.Approved, Investigational
RacecadotrilThe serum concentration of Bromocriptine can be increased when it is combined with Racecadotril.Investigational
RacepinephrineBromocriptine may increase the hypertensive and vasoconstricting activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Raclopride.Investigational
RactopamineBromocriptine may increase the hypertensive and vasoconstricting activities of Ractopamine.Vet Approved
RaloxifeneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Raloxifene.Approved, Investigational
RamiprilThe serum concentration of Bromocriptine can be increased when it is combined with Ramipril.Approved
RanitidineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Bromocriptine.Approved, Investigational
RasagilineThe metabolism of Bromocriptine can be decreased when combined with Rasagiline.Approved
RegorafenibThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Remifentanil.Approved
RemikirenThe serum concentration of Bromocriptine can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Remoxipride.Approved, Withdrawn
RepaglinideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Repaglinide.Approved, Investigational
ReproterolBromocriptine may increase the hypertensive and vasoconstricting activities of Reproterol.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Reserpine.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Resveratrol.Approved, Experimental, Investigational
RifabutinThe metabolism of Bromocriptine can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Bromocriptine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Bromocriptine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Bromocriptine.Approved, Investigational
RilmenidineBromocriptine may increase the hypertensive and vasoconstricting activities of Rilmenidine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Bromocriptine.Approved
RimiterolBromocriptine may increase the hypertensive and vasoconstricting activities of Rimiterol.Experimental
RiociguatThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Riociguat.Approved
RisperidoneBromocriptine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ritanserin.Investigational
RitobegronBromocriptine may increase the hypertensive and vasoconstricting activities of Ritobegron.Investigational
RitodrineBromocriptine may increase the hypertensive and vasoconstricting activities of Ritodrine.Approved, Investigational
RitonavirThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Bromocriptine can be increased when it is combined with Rivaroxaban.Approved
RivastigmineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Rivastigmine.Approved, Investigational
RizatriptanBromocriptine may increase the vasoconstricting activities of Rizatriptan.Approved
RolitetracyclineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Rolitetracycline.Approved
RomifidineBromocriptine may increase the hypertensive and vasoconstricting activities of Romifidine.Vet Approved
RopiniroleBromocriptine may increase the vasoconstricting activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ropivacaine.Approved
RosoxacinRosoxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Bromocriptine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Rotigotine.Approved
RoxithromycinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Roxithromycin.Approved, Investigational, Withdrawn
RP5063The therapeutic efficacy of Bromocriptine can be decreased when used in combination with RP5063.Investigational
RucaparibThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Rucaparib.Approved, Investigational
RufloxacinRufloxacin may increase the hypoglycemic activities of Bromocriptine.Experimental
RutinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Rutin.Experimental, Investigational
S-3304The serum concentration of Bromocriptine can be increased when it is combined with S-3304.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sacubitril.Approved
SafrazineThe metabolism of Bromocriptine can be decreased when combined with Safrazine.Withdrawn
SalbutamolBromocriptine may increase the hypertensive and vasoconstricting activities of Salbutamol.Approved, Vet Approved
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational, Vet Approved
SalmeterolBromocriptine may increase the hypertensive and vasoconstricting activities of Salmeterol.Approved
SaquinavirThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Bromocriptine can be increased when it is combined with Saxagliptin.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Bromocriptine.Approved, Vet Approved
SelegilineThe metabolism of Bromocriptine can be decreased when combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Bromocriptine.Approved
SiltuximabThe serum concentration of Bromocriptine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Bromocriptine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Bromocriptine.Approved
SirolimusThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sirolimus.Approved, Investigational
SitafloxacinSitafloxacin may increase the hypoglycemic activities of Bromocriptine.Experimental, Investigational
SitagliptinThe serum concentration of Bromocriptine can be increased when it is combined with Sitagliptin.Approved, Investigational
SitaxentanThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sitaxentan.Approved, Investigational, Withdrawn
SivelestatThe serum concentration of Bromocriptine can be increased when it is combined with Sivelestat.Investigational
SolabegronBromocriptine may increase the hypertensive and vasoconstricting activities of Solabegron.Investigational
SolithromycinThe serum concentration of Bromocriptine can be increased when it is combined with Solithromycin.Investigational
SomatostatinThe serum concentration of Bromocriptine can be increased when it is combined with Somatostatin.Approved, Investigational
SorafenibThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sorafenib.Approved, Investigational
SotalolBromocriptine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
SpiraprilThe serum concentration of Bromocriptine can be increased when it is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Bromocriptine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneStanolone may increase the hypoglycemic activities of Bromocriptine.Illicit, Investigational
StanozololStanozolol may increase the hypoglycemic activities of Bromocriptine.Approved, Vet Approved
StiripentolThe serum concentration of Bromocriptine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sufentanil.Approved, Investigational
SulfamethoxazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sulfamethoxazole.Approved
SulfanilamideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sulfanilamide.Approved
SulfinpyrazoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sultopride.Experimental
SumatriptanBromocriptine may increase the vasoconstricting activities of Sumatriptan.Approved, Investigational
SynephrineBromocriptine may increase the hypertensive and vasoconstricting activities of Synephrine.Experimental
TacrolimusThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tacrolimus.Approved, Investigational
TadalafilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tadalafil.Approved, Investigational
TalinololBromocriptine may increase the atrioventricular blocking (AV block) activities of Talinolol.Investigational
TamoxifenThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tamoxifen.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tapentadol.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Bromocriptine.Approved
TelaprevirThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Telmisartan.Approved, Investigational
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Bromocriptine.Withdrawn
TemocaprilThe serum concentration of Bromocriptine can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Temsirolimus.Approved
TeniposideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Teniposide.Approved
TerazosinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Terazosin.Approved
TerbutalineBromocriptine may increase the hypertensive and vasoconstricting activities of Terbutaline.Approved
TerfenadineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Terfenadine.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Bromocriptine.Experimental
TertatololBromocriptine may increase the atrioventricular blocking (AV block) activities of Tertatolol.Experimental
TesmilifeneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tesmilifene.Investigational
TestosteroneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Testosterone cypionate.Approved
Testosterone enanthateThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Testosterone enanthate.Approved
Testosterone propionateTestosterone propionate may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Testosterone undecanoate.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Bromocriptine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Thiopropazate.Experimental
ThioproperazineThe therapeutic efficacy of Thioproperazine can be decreased when used in combination with Bromocriptine.Approved
ThioridazineThe therapeutic efficacy of Thioridazine can be decreased when used in combination with Bromocriptine.Approved, Withdrawn
ThiorphanThe serum concentration of Bromocriptine can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe therapeutic efficacy of Thiothixene can be decreased when used in combination with Bromocriptine.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tiapride.Approved, Investigational
TicagrelorThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ticlopidine.Approved
TimololBromocriptine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tioconazole.Approved
TipranavirThe serum concentration of Bromocriptine can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Bromocriptine.Approved, Investigational
TocilizumabThe serum concentration of Bromocriptine can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tofisopam.Approved
TolazolineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe metabolism of Bromocriptine can be decreased when combined with Toloxatone.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Bromocriptine.Approved
TopiroxostatThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Bromocriptine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Bromocriptine can be increased when it is combined with Trandolapril.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Bromocriptine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TretoquinolBromocriptine may increase the hypertensive and vasoconstricting activities of Tretoquinol.Experimental
TriamtereneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Triamterene.Approved
TrifluoperazineThe therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Triflupromazine.Approved, Vet Approved
TrimipramineTrimipramine may decrease the antihypertensive activities of Bromocriptine.Approved
TroglitazoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Troglitazone.Investigational, Withdrawn
Trolamine salicylateTrolamine salicylate may increase the hypoglycemic activities of Bromocriptine.Approved
TroleandomycinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Troleandomycin.Approved
TropisetronTropisetron may increase the serotonergic activities of Bromocriptine.Approved, Investigational
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational, Withdrawn
TulobuterolBromocriptine may increase the hypertensive and vasoconstricting activities of Tulobuterol.Investigational
TylosinThe serum concentration of Bromocriptine can be increased when it is combined with Tylosin.Vet Approved
UbenimexThe serum concentration of Bromocriptine can be increased when it is combined with Ubenimex.Experimental, Investigational
UlinastatinThe serum concentration of Bromocriptine can be increased when it is combined with Ulinastatin.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Valsartan.Approved, Investigational
VapreotideThe serum concentration of Bromocriptine can be increased when it is combined with Vapreotide.Approved, Investigational
VemurafenibThe serum concentration of Bromocriptine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Veralipride.Experimental
VerapamilThe metabolism of Bromocriptine can be decreased when combined with Verapamil.Approved
VilazodoneBromocriptine may increase the vasoconstricting activities of Vilazodone.Approved
VildagliptinThe serum concentration of Bromocriptine can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Vinblastine.Approved
VincristineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Vincristine.Approved, Investigational
VincristineThe excretion of Vincristine can be decreased when combined with Bromocriptine.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Voriconazole.Approved, Investigational
VortioxetineBromocriptine may increase the vasoconstricting activities of Vortioxetine.Approved, Investigational
XamoterolBromocriptine may increase the hypertensive and vasoconstricting activities of Xamoterol.Experimental
XimelagatranThe serum concentration of Bromocriptine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineBromocriptine may increase the hypertensive and vasoconstricting activities of Xylazine.Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Bromocriptine can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZafirlukastThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Zafirlukast.Approved, Investigational
ZimelidineZimelidine may increase the hypoglycemic activities of Bromocriptine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ziprasidone.Approved
ZofenoprilThe serum concentration of Bromocriptine can be increased when it is combined with Zofenopril.Experimental
ZolmitriptanBromocriptine may increase the vasoconstricting activities of Zolmitriptan.Approved, Investigational
ZotepineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Zotepine.Approved, Investigational, Withdrawn
ZucapsaicinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Bromocriptine.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.

References

Synthesis Reference

Luigi Moro, Achille Fiori, Alberto Natali, "Processes for the preparation of pharmaceutical compositions containing bromocriptine having high stability and related products." U.S. Patent US5066495, issued May, 1988.

US5066495
General References
  1. Banihashemi B, Albert PR: Dopamine-D2S receptor inhibition of calcium influx, adenylyl cyclase, and mitogen-activated protein kinase in pituitary cells: distinct Galpha and Gbetagamma requirements. Mol Endocrinol. 2002 Oct;16(10):2393-404. [PubMed:12351703]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
  4. Malgaroli A, Vallar L, Elahi FR, Pozzan T, Spada A, Meldolesi J: Dopamine inhibits cytosolic Ca2+ increases in rat lactotroph cells. Evidence of a dual mechanism of action. J Biol Chem. 1987 Oct 15;262(29):13920-7. [PubMed:2443499]
  5. Nishina Y, Takano K, Yasufuku-Takano J, Teramoto A, Fujita T: Mechanism of D(2) agonist-induced inhibition of GH secretion from human GH-secreting adenoma cells. Endocr J. 2005 Dec;52(6):775-9. [PubMed:16410672]
  6. Vallar L, Meldolesi J: Mechanisms of signal transduction at the dopamine D2 receptor. Trends Pharmacol Sci. 1989 Feb;10(2):74-7. [PubMed:2655242]
  7. Vallar L, Vicentini LM, Meldolesi J: Inhibition of inositol phosphate production is a late, Ca2+-dependent effect of D2 dopaminergic receptor activation in rat lactotroph cells. J Biol Chem. 1988 Jul 25;263(21):10127-34. [PubMed:2839476]
External Links
Human Metabolome Database
HMDB0015331
KEGG Drug
D03165
KEGG Compound
C06856
PubChem Compound
31101
PubChem Substance
46505504
ChemSpider
28858
BindingDB
81993
ChEBI
3181
ChEMBL
CHEMBL493
Therapeutic Targets Database
DAP001462
PharmGKB
PA448671
HET
08Y
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Bromocriptine
ATC Codes
G02CB01 — BromocriptineN04BC01 — Bromocriptine
AHFS Codes
  • 28:36.20.04 — Ergot-derivative Dopamine Receptor Agonists
PDB Entries
3ua1 / 5vcg
FDA label
Download (105 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentEndometriosis of Uterus1
1CompletedTreatmentType 2 Diabetes Mellitus1
1, 2Not Yet RecruitingTreatmentDiabetic Macular Edema (DME)1
1, 2Not Yet RecruitingTreatmentFevers / Intracerebral Hemorrhage / Stroke, Ischemic / Subarachnoid Hemorrhage / Subdural haematoma / Traumatic Brain Injury (TBI)1
2CompletedTreatmentPeripartum Cardiomyopathy1
2Not Yet RecruitingTreatmentOvarian Hyperstimulation Syndrome1
2RecruitingTreatmentBMI >30 kg/m21
2RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
2SuspendedTreatmentMental Retardation / Stereotyped Behavior1
3CompletedTreatmentIdiopathic Parkinson's Disease1
3CompletedTreatmentParkinson's Disease (PD)2
3CompletedTreatmentType 2 Diabetes Mellitus1
3Not Yet RecruitingTreatmentPeripartum Cardiomyopathy1
3TerminatedTreatmentType 2 Diabetes Mellitus1
3Unknown StatusNot AvailableInsulin Resistance / Polycystic Ovarian Syndrome1
4Active Not RecruitingTreatmentType 2 Diabetes Mellitus1
4CompletedTreatmentParkinson's Disease (PD)2
4CompletedTreatmentType 2 Diabetes Mellitus1
4RecruitingTreatmentDiabetic Autonomic Neuropathy1
4Unknown StatusTreatmentHigh Blood Pressure (Hypertension) / Hyperaldosteronism1
Not AvailableActive Not RecruitingBasic ScienceAddictions1
Not AvailableCompletedNot AvailableBMI >30 kg/m21
Not AvailableCompletedNot AvailableInsulin Sensitivity1
Not AvailableCompletedTreatmentCirrhosis Related Parkinsonism / Hepatic/Cirrhosis Related Parkinsonism1
Not AvailableTerminatedTreatmentGraves Ophthalmopathy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Amerisource Health Services Corp.
  • Cadila Healthcare Ltd.
  • Heartland Repack Services LLC
  • Kaiser Foundation Hospital
  • Lek Pharmaceuticals Inc.
  • Medisca Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Novartis AG
  • Paddock Labs
  • Pharmaceutical Utilization Management Program VA Inc.
  • Physicians Total Care Inc.
  • Poli Industria Chimica SPA
  • Resource Optimization and Innovation LLC
  • Sandoz
  • Zydus Pharmaceuticals
Dosage forms
FormRouteStrength
CapsuleOral5 mg
TabletOral2.5 mg
CapsuleOral5 mg/1
TabletOral.8 mg/1
CapsuleOral5.0 mg
Capsule, gelatin coatedOral5 mg/1
TabletOral2.5 mg/1
Prices
Unit descriptionCostUnit
Bromocriptine mesylate powd384.03USD g
Parlodel 5 mg capsule9.25USD capsule
Parlodel 2.5 mg tablet5.64USD tablet
Bromocriptine Mesylate 5 mg capsule5.21USD capsule
Bromocriptine Mesylate 2.5 mg tablet2.28USD tablet
Bromocriptine 2.5 mg tablet2.18USD tablet
Apo-Bromocriptine 5 mg Capsule1.02USD capsule
Pms-Bromocriptine 5 mg Capsule1.02USD capsule
Apo-Bromocriptine 2.5 mg Tablet0.57USD tablet
Pms-Bromocriptine 2.5 mg Tablet0.57USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5716957No1995-02-102015-02-10Us
US5468755No1992-11-212012-11-21Us
US8613947No2012-04-302032-04-30Us
US7888310No2003-07-252023-07-25Us
US8431155No2012-04-302032-04-30Us
US8137993No2003-07-252023-07-25Us
US8137992No2003-07-252023-07-25Us
US8137994No2003-07-252023-07-25Us
US8877708No2010-06-072030-06-07Us
US9192576No2012-04-302032-04-30Us
US9522117No2012-04-302032-04-30Us
US9352025No2010-06-072030-06-07Us
US9700555No2012-04-302032-04-30Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)215-218Fluckiger, E.,Troxler, F. and Hofmann, A,; US. Patent 3,752,814; August 14, 1973; assigned to Sandoz Ltd., Switzerland. Fluckiger, E., Troxler, F. and Hofmann, A.; U.S. Patent 3,752,888; August 14, 1973; assigned to Sandoz Ltd., Switzerland.
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0858 mg/mLALOGPS
logP3.2ALOGPS
logP3.89ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)9.68ChemAxon
pKa (Strongest Basic)6.71ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.21 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity165.51 m3·mol-1ChemAxon
Polarizability66.44 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.915
Blood Brain Barrier-0.9845
Caco-2 permeable-0.6618
P-glycoprotein substrateSubstrate0.8881
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterNon-inhibitor0.837
CYP450 2C9 substrateNon-substrate0.8345
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7454
CYP450 1A2 substrateNon-inhibitor0.9031
CYP450 2C9 inhibitorInhibitor0.8326
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5149
Ames testNon AMES toxic0.7879
CarcinogenicityNon-carcinogens0.9353
BiodegradationNot ready biodegradable0.9973
Rat acute toxicity2.7499 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9313
hERG inhibition (predictor II)Inhibitor0.5
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as lysergamides. These are amides of Lysergic acids.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Ergoline and derivatives
Sub Class
Lysergic acids and derivatives
Direct Parent
Lysergamides
Alternative Parents
Indoloquinolines / Benzoquinolines / Pyrroloquinolines / N-acyl-alpha amino acids and derivatives / 3-alkylindoles / Isoindoles and derivatives / Aralkylamines / N-alkylpiperazines / Aryl bromides / Benzenoids
show 18 more
Substituents
Lysergic acid amide / Indoloquinoline / Benzoquinoline / N-acyl-alpha amino acid or derivatives / Pyrroloquinoline / Alpha-amino acid or derivatives / Quinoline / 3-alkylindole / Indole / Indole or derivatives
show 42 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
indole alkaloid (CHEBI:3181)

Targets

Details
1. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Cavallotti C, Nuti F, Bruzzone P, Mancone M: Age-related changes in dopamine D2 receptors in rat heart and coronary vessels. Clin Exp Pharmacol Physiol. 2002 May-Jun;29(5-6):412-8. [PubMed:12010185]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  3. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  4. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
  5. Lahlou S: Cardiovascular responses to intrathecal dopamine receptor agonists in conscious DOCA-salt hypertensive rats. Fundam Clin Pharmacol. 1999;13(6):624-34. [PubMed:10626749]
  6. Lahlou S, Araujo Lima PF, Interaminense LF, Duarte GP: Blunted central bromocriptine-induced tachycardia in conscious, malnourished rats. Pharmacol Toxicol. 2003 Apr;92(4):189-94. [PubMed:12753422]
  7. Lahlou S, Lima GC, Leao-Filho CS, Duarte GP: Effects of long-term pretreatment with isoproterenol on bromocriptine-induced tachycardia in conscious rats. Can J Physiol Pharmacol. 2000 Mar;78(3):260-5. [PubMed:10721819]
  8. Stefaneanu L, Kovacs K, Horvath E, Buchfelder M, Fahlbusch R, Lancranjan L: Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine. 2001 Apr;14(3):329-36. [PubMed:11444429]
Details
2. D(3) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1D
Uniprot ID
P28221
Uniprot Name
5-hydroxytryptamine receptor 1D
Molecular Weight
41906.38 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, Ouwens DM, Pijl H, Guigas B: The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem Pharmacol. 2010 Jun 15;79(12):1827-36. doi: 10.1016/j.bcp.2010.01.029. Epub 2010 Feb 4. [PubMed:20138024]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, Ouwens DM, Pijl H, Guigas B: The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem Pharmacol. 2010 Jun 15;79(12):1827-36. doi: 10.1016/j.bcp.2010.01.029. Epub 2010 Feb 4. [PubMed:20138024]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, Ouwens DM, Pijl H, Guigas B: The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem Pharmacol. 2010 Jun 15;79(12):1827-36. doi: 10.1016/j.bcp.2010.01.029. Epub 2010 Feb 4. [PubMed:20138024]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation...
Gene Name
HTR2B
Uniprot ID
P41595
Uniprot Name
5-hydroxytryptamine receptor 2B
Molecular Weight
54297.41 Da
References
  1. Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I: Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol. 2008 Oct 10;594(1-3):32-8. doi: 10.1016/j.ejphar.2008.07.040. Epub 2008 Jul 30. [PubMed:18703043]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I: Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol. 2008 Oct 10;594(1-3):32-8. doi: 10.1016/j.ejphar.2008.07.040. Epub 2008 Jul 30. [PubMed:18703043]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1B
Uniprot ID
P28222
Uniprot Name
5-hydroxytryptamine receptor 1B
Molecular Weight
43567.535 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I: Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol. 2008 Oct 10;594(1-3):32-8. doi: 10.1016/j.ejphar.2008.07.040. Epub 2008 Jul 30. [PubMed:18703043]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Details
13. D(1B) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD5
Uniprot ID
P21918
Uniprot Name
D(1B) dopamine receptor
Molecular Weight
52950.5 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Details
14. D(1A) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR7
Uniprot ID
P34969
Uniprot Name
5-hydroxytryptamine receptor 7
Molecular Weight
53554.43 Da
References
  1. Knight JA, Smith C, Toohey N, Klein MT, Teitler M: Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists. Mol Pharmacol. 2009 Feb;75(2):374-80. doi: 10.1124/mol.108.052084. Epub 2008 Nov 7. [PubMed:18996971]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Fernando H, Halpert JR, Davydov DR: Resolution of multiple substrate binding sites in cytochrome P450 3A4: the stoichiometry of the enzyme-substrate complexes probed by FRET and Job's titration. Biochemistry. 2006 Apr 4;45(13):4199-209. [PubMed:16566594]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  3. Nath A, Grinkova YV, Sligar SG, Atkins WM: Ligand binding to cytochrome P450 3A4 in phospholipid bilayer nanodiscs: the effect of model membranes. J Biol Chem. 2007 Sep 28;282(39):28309-20. Epub 2007 Jun 15. [PubMed:17573349]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113]
  2. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267]
  3. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524]
  4. Renaud JP, Davydov DR, Heirwegh KP, Mansuy D, Hui Bon Hoa GH: Thermodynamic studies of substrate binding and spin transitions in human cytochrome P-450 3A4 expressed in yeast microsomes. Biochem J. 1996 Nov 1;319 ( Pt 3):675-81. [PubMed:8920966]

Drug created on June 13, 2005 07:24 / Updated on May 22, 2018 23:50